Cepheid at the forefront of diagnostic development and what the future holds-John L. Bishop-03/19/2013 - 8:30am

Event Information
Event Topic: 
Cepheid at the forefront of diagnostic development and what the future holds
Event Date: 
03/19/2013 - 8:30am
Event Location: 
Sunnyvale City Council Chambers, 456 West Olive Ave., Sunnyale, CA
Speaker Information
Event Speaker: 
John L. Bishop
Event Speaker Title: 
Chairman and Chief Executive Officer
Event Speaker Company: 
Cepheid
Event Speaker Bio: 

John Bishop

Mr. Bishop joined Cepheid as Chief Executive Officer and as a director in April 2002. Mr. Bishop served as President and a director of Vysis, Inc., a genomic disease management company that was acquired by Abbott, from 1993 to 2002 and as Chief Executive Officer from 1996 to 2002. From 1991 until 1993, Mr. Bishop was Chairman and Chief Executive Officer of MicroProbe Corporation, a biotechnology company, and, from 1987 until 1991, of Source Scientific Systems, a biomedical instrument manufacturing company. From 1984 to 1986, Mr. Bishop was President and Chief Operating Officer of Gen-Probe, Inc. From 1968 to 1984, Mr. Bishop held various management positions with American Hospital Supply Company and its affiliates, including a three-year assignment in Japan as an Executive Vice President and Chief Executive Officer of International Reagents Corp., a joint venture between American Hospital Supply Company and Green Cross Corporation. Mr. Bishop currently serves as a director of Conceptus, Inc. In addition, he is a member of the Health Section Governing Board of the Biotechnology Industry Organization and a member of the AdvaMed Dx Board, a division of The Advanced Medical Technology Association.

Event Details
Cost: 
$0
Event Details: 

Bio2Device Group, Tuesday Morning, March 19, 2013

Speaker: John L. Bishop, Chairman and Chief Executive Officer
Topic: "Cepheid at the forefront of diagnostic development and what the future holds"
Date and Time: Tuesday, March 19, 2013, 8:30 – 10:30 am
Location: Sunnyvale City Council Chambers, 456 W. Olive, Sunnyvale
Cost: Free
No registration is required.

Topic Description
In the aftermath of the September 11th 2001 attacks, a second shockwave was sent around the world in the form of Anthrax-spore-laden letters carried by the US Postal Service to high profile domestic targets. Cepheid, together with Northrup Grumman, was asked to respond by developing a PCR-based mail surveillance system to bring the power of molecular diagnostics to a decentralized testing approach that can be implemented in a low skill environment on a 24/7 basis. At the time, this was viewed as an impossible task given the available molecular technologies, which needed to be run in batches from central labs using highly skilled personnel.

Eight years and nearly 11 million cartridges later (with no false positives to date), this program remains in effect as the most successful biothreat detection program in the world. More importantly, it proved that molecular diagnostic technologies were ready for implementation on a distributed basis…and no longer limited by skill sets or geography. The medical value of rapid, decentralized testing has been dramatically illustrated by the global impact of Cepheid technology for detection of tuberculosis, and is a now a driver behind the mainstreaming of molecular testing in laboratories throughout the world.

Speaker Bio
Mr. Bishop joined Cepheid as Chief Executive Officer and as a director in April 2002. Mr. Bishop served as President and a director of Vysis, Inc., a genomic disease management company that was acquired by Abbott, from 1993 to 2002 and as Chief Executive Officer from 1996 to 2002. From 1991 until 1993, Mr. Bishop was Chairman and Chief Executive Officer of MicroProbe Corporation, a biotechnology company, and, from 1987 until 1991, of Source Scientific Systems, a biomedical instrument manufacturing company. From 1984 to 1986, Mr. Bishop was President and Chief Operating Officer of Gen-Probe, Inc. From 1968 to 1984, Mr. Bishop held various management positions with American Hospital Supply Company and its affiliates, including a three-year assignment in Japan as an Executive Vice President and Chief Executive Officer of International Reagents Corp., a joint venture between American Hospital Supply Company and Green Cross Corporation. Mr. Bishop currently serves as a director of Conceptus, Inc. In addition, he is a member of the Health Section Governing Board of the Biotechnology Industry Organization and a member of the AdvaMed Dx Board, a division of The Advanced Medical Technology Association.

Payment Options Dec 12th Evening Event

Attention B2DG members: You must login to your account first to see the members' early-bird admission rate.
If you are not a B2DG member or if you had missed the early-bird deadline, the registration fee is $20. Please follow these instructions to register.

We use PAYPAL to process your online payment. Print and bring a copy of your online receipt with you. If space permits, walk-ins are welcomed; please be prepared to pay $25 at the door (cash or check). There is no refund, exchange, or transfer. Thank you for your cooperation.
To register now, please select your meal preference from the pull-down menu below and enter the attendee's information. Then click on the "Pay Now" button to reach the PayPal payment page. Each attendee must be registered separately.
Make sure you enter the attendee's meal choice, name, and email address.


Meal Choice
Name of Attendee
Email Address